T3 Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 31

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $502M

  • Investors
  • 1

T3 Pharmaceuticals General Information

Description

Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system to treat solid cancer tumors, enabling healthcare providers to improve the lives of patients and cure them.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Hegenheimermattweg 167A
  • 4123 Allschwil
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Boehringer Ingelheim
Vertical(s)
Corporate Office
  • Hegenheimermattweg 167A
  • 4123 Allschwil
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

T3 Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 22-Nov-2023 $502M Completed Clinical Trials - Phase 1
9. Later Stage VC 22-Jul-2020 Completed Clinical Trials - Phase 1
8. Early Stage VC 26-Sep-2019 Completed Clinical Trials - Phase 1
7. Grant 28-May-2019 Completed Clinical Trials - Phase 1
6. Accelerator/Incubator 30-Jan-2018 Completed Clinical Trials - Phase 1
5. Angel (individual) 28-Nov-2016 Completed Startup
4. Grant 01-Jan-2016 Completed Startup
3. Grant Completed Startup
2. University Spin-Out 01-May-2015 Completed Startup
1. Accelerator/Incubator Completed Startup
To view T3 Pharmaceuticals’s complete valuation and funding history, request access »

T3 Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preference
Ordinary
To view T3 Pharmaceuticals’s complete cap table history, request access »

T3 Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary prot
Drug Discovery
Allschwil, Switzerland
31 As of 2026

Pasadena, CA
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

T3 Pharmaceuticals Competitors (59)

One of T3 Pharmaceuticals’s 59 competitors is Meditope Biosciences, a Formerly VC-backed company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Meditope Biosciences Formerly VC-backed Pasadena, CA
Anaveon Venture Capital-Backed Basel, Switzerland
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
RootPath Venture Capital-Backed Framingham, MA
Memgen Venture Capital-Backed Houston, TX
You’re viewing 5 of 59 competitors. Get the full list »

T3 Pharmaceuticals Patents

T3 Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022244124-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021
AU-2022244124-A9 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021
CA-3210774-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021
EP-4313310-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021
EP-4314036-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021 A61P35/00
To view T3 Pharmaceuticals’s complete patent history, request access »

T3 Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

T3 Pharmaceuticals Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
BaseLaunch Accelerator/Incubator
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
Gebert Rüf Foundation Accelerator/Incubator
Innosuisse Government
Reference Capital Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

T3 Pharmaceuticals FAQs

  • When was T3 Pharmaceuticals founded?

    T3 Pharmaceuticals was founded in 2015.

  • Where is T3 Pharmaceuticals headquartered?

    T3 Pharmaceuticals is headquartered in Allschwil, Switzerland.

  • What is the size of T3 Pharmaceuticals?

    T3 Pharmaceuticals has 31 total employees.

  • What industry is T3 Pharmaceuticals in?

    T3 Pharmaceuticals’s primary industry is Drug Discovery.

  • Is T3 Pharmaceuticals a private or public company?

    T3 Pharmaceuticals is a Private company.

  • What is the current valuation of T3 Pharmaceuticals?

    The current valuation of T3 Pharmaceuticals is .

  • What is T3 Pharmaceuticals’s current revenue?

    The current revenue for T3 Pharmaceuticals is .

  • How much funding has T3 Pharmaceuticals raised over time?

    T3 Pharmaceuticals has raised $41.8M.

  • Who are T3 Pharmaceuticals’s investors?

    BaseLaunch, Boehringer Ingelheim Venture Fund, Gebert Rüf Foundation, Innosuisse, and Reference Capital are 5 of 11 investors who have invested in T3 Pharmaceuticals.

  • Who are T3 Pharmaceuticals’s competitors?

    Meditope Biosciences, Anaveon, Inovio Pharmaceuticals, RootPath, and Memgen are some of the 59 competitors of T3 Pharmaceuticals.

  • When was T3 Pharmaceuticals acquired?

    T3 Pharmaceuticals was acquired on 22-Nov-2023.

  • Who acquired T3 Pharmaceuticals?

    T3 Pharmaceuticals was acquired by Boehringer Ingelheim.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process